AngioDynamics (ANGO) – Investment Analysts’ Recent Ratings Updates

AngioDynamics (NASDAQ: ANGO) recently received a number of ratings updates from brokerages and research firms:

• 7/17/2026 – AngioDynamics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – AngioDynamics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/15/2026 – AngioDynamics had its price target raised by Canaccord Genuity Group Inc. from $16.00 to $20.00. They now have a “buy” rating on the stock.
• 7/15/2026 – AngioDynamics had its price target raised by HC Wainwright from $16.00 to $19.00. They now have a “buy” rating on the stock.

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.